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Summary Quality of life is impaired in patients with epilepsy and can be improved
by effective therapy. Randomised clinical trials have shown that lamotrigine treat-
ment is associated with improved quality of life. However, little information is
available on quality of life or treatment effects in patients with epilepsy in the
general population. The objective of this study was to estimate the impact of
lamotrigine on quality of life in a naturalistic treatment setting. The study included
adult patients with epilepsy in whom lamotrigine therapy was initiated. Each subject
completed the Quality of Life in Epilepsy Inventory (QOLIE)-31 quality of life ques-
tionnaire at inclusion and at a follow-up visit in the next 4 months. Demographic
information and medical history were provided by the investigator. These were
evaluated as potential determinants of change in quality of life using logistic
regression. Three hundred and forty-one patients were evaluated, 192 starting
lamotrigine in combination with another drug, 90 as a first-line monotherapy, 45
as a switch from another drug and 14 as a reduction to monotherapy from a previous
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combination. Baseline scores on the QOLIE-31 ranged from 53.8 in the combination
group to 69.5 in the first-line group. 34.6% of patients were considered to be
responders, with no significant differences between treatment regimen. Most
improvement was seen for the energy—fatigue and medication effects subscales
and, for the first-line group, seizure worry. Seizure type was the only determinant of
improvement of quality of life identified. In conclusion, lamotrigine treatment is
associated with improved quality of life, regardless of treatment regimen.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Quality of life is impaired in subjects with epilepsy
compared with individuals of the same age and sex
in the general population.1,2 Several consequences
of epilepsy contribute to the mediocre quality of life
in these subjects, including worry about seizures,
functional impairment (for example, the inability to
drive), educational handicap, difficulties with rela-
tionships and depression. In addition, the side-
effects of certain antiepileptic drugs may contri-
bute to poor quality of life.
Improvement of quality of life in patients with
epilepsy is thus a pertinent treatment objective,
and several studies have demonstrated that initia-
tion of an antiepileptic drug treatment that effec-
tively controls seizures is associated with an
amelioration of quality of life.2,3 A number of instru-
ments are available to assess health-related quality
of life in individuals with epilepsy,4,5 including both
generic measures such as the SF-366 and the Quality
Of Life Assessment (QOLAS)7 and specific measures
such as the Side Effects And Life Satisfaction Scale
(SEALS),8 the Liverpool Impact of Epilepsy scale
(LIE),9 the Quality of Life in Newly Diagnosed Epi-
lepsy Instrument (NEWQOL),10 the Epilepsy and
Learning Disability Quality of Life (ELDQOL),11 the
Quality of life in Childhood Epilpesy (QOLCE)12 and
the different versions of the Quality of Life in
Epilepsy Inventory (QOLIE).13—17 The QOLIE-31, a
31-item measure, initially developed and validated
in the US from a longer 89-item version,13,15 has
been used extensively. This scale has been shown to
be responsive to change in epileptic patients18—21
and been used to measure effects of antiepileptic
drug treatment on quality of life in a variety of
clinical studies.22—25 The QOLIE-31 has been trans-
lated into a number of languages, including French15
and a psychometric validation of the French version
of the scale in a community setting has recently
been published.26
The new antiepileptic drugs introduced over the
last 10—15 years are generally regarded as being
superior to previous treatments in terms of patient
acceptability, due to an improved side-effect profile
and more convenient administration. Most of thesedrugs, however, are not used as first-line treatment
for epilepsy. Lamotrigine is the only one of this
generation that has been approved for use as a
first-line treatment in monotherapy, and has been
shown to be efficacious in the treatment of both
generalised and focal epilepsy syndromes.
A number of studies have evaluated the impact of
lamotrigine treatment on quality of life in patients
with epilepsy in a variety of clinical settings, using a
number of measures, including the SF-36,27 the
QOLAS,28 the LEI,29 the ELDQOL,30 the QOLIE-89,31
the QOLIE-3125,32,33 and the SEALS.32,34,35 These
studies have consistently demonstrated an improve-
ment in quality of life in patients receiving lamo-
trigine.36
The majority of quality of life studies carried out
to date have been performed as randomised or open
clinical trials, and it is not clear to what extent the
benefits observed can be generalised to routine care
of epilepsy in the community. Such data are needed
to evaluate and compare the utility of different
management strategies for epilepsy from a public
health perspective. For this reason, we have made
use of a large-scale registry of patients with epilepsy
treated with lamotrigine in France (EPSILAM)37 to
determine the change in quality of life measured
with the QOLIE-31 following initiation of lamotrigine
treatment. In addition, we have compared the
impact on quality of life of different treatment
regimens using lamotrigine as monotherapy or in
combination with other antiepileptic drugs.Methods
Study background and design
The EPSILAM study was a prospective, naturalistic,
observational pharmacoepidemiological study per-
formed in France between November 2000 and
October 2003 in subjects with epilepsy recruited
in a community medicine or hospital setting.
The primary objective of the study was to collect
pharmacoepidemiological data on patients treated
with lamotrigine under real-life conditions and com-
pare these with recommended prescribing practice
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phase and a longitudinal phase. The data on pre-
scription practice were published separately in a
French-language journal. A secondary objective of
the study was to assess quality of life in lamotrigine-
treated patients during the longitudinal phase.
Inclusion of the QOLIE-31 scale allowed data on
quality of life to be compared with data previously
obtained with this questionnaire in other studies.
Quality of life data could be evaluated for the
subgroup of patients fulfilling the following three
conditions. Firstly, the analysis was restricted to
patients over 16 years of age, the QOLIE-31 not
having been validated for younger children. Sec-
ondly, comparison of scores before and after insti-
tution of a lamotrigine treatment required the
patient to have returned for a second spontaneous
or programmed consultation. It should be noted
that, given the observational design of the study,
this second consultation was not imposed by the
study protocol. Finally, the analysis required a glo-
bal QOLIE-31 score to be calculable at both study
visits.
Participating investigators
The study was implemented by neurologists chosen
at random from a list of all neurologists practising in
France provided by Ce´ge´dim, an affiliate of the
French National Statistics Office. The random sam-
pling was stratified by geographical region and by
three groups of practitioner defined by their prac-
tice setting, namely community-based neurologists,
hospital-based neurologists and epilepsy specialists.
In order to obtain a balanced number of subjects par
neurologist group, to ensure that the sample of
participating neurologists would be sufficiently
representative and to take into account the number
of neurologists practicing in each of the three
groups, it was aimed to recruit community neurol-
ogists, hospital neurologists and epilepsy specialists
in a ratio of 23:13:8. Each neurologist in these three
groups were expected to include two, four and six
patients, respectively. In case of non-participation,
neurologists were replaced by the following name
on the random list for the relevant stratum.
During the course of the study, lamotrigine in
monotherapy was licensed for first-line treatment
of epilepsy in patients over 12 years old. For this
reason, an ancillary study was initiated to capture
data on this patient group. To this end, some of the
neurologists who had accepted to participate in the
original cohort (community-based neurologists, hos-
pital-based neurologists and epilepsy specialists in a
ratio of 2:1:1) were subsequently invited to recruit
patients on monotherapy.Selection of patients
Each participating neurologist was expected to
screen the next 25 patients treated with lamotrigine
seen in consultation, regardless of epilepsy type or
treatment regimen. The inclusion period for the
study lasted between 6 and 12 months. From this
sample, patients fulfilling the entry criteria (patients
changing lamotrigine treatment regimen) were
included into the longitudinal study until the prede-
fined quota for the investigator (two to six patients
per investigator, according to practice setting for the
original cohort and two to three in the first-line
monotherapy group) had been reached. The remain-
ing patients screened who were not changing
lamotrigine treatment regimen (except for dose
adjustment) were entered into a patient registry.
Quality of life datawas not collected in these registry
patients,who are not discussed further in this report.
The inclusion criteria for the longitudinal study
related to the treatment regimen used for lamotri-
gine. Patients could be included either if they had
initiated lamotrigine treatment within the previous
30 days or of they had transferred from a combina-
tion treatment with lamotrigine to monotherapy
with lamotrigine alone during this period. Patients
participating in clinical trials and infants less than 2
years old were excluded from the study. For the
first-line monotherapy subgroup, patients less than
12 years old were not included, such an indication
not being approved in this patient group.
The patients included were divided into four
analysis groups according to treatment regimen.
These were the Add-on group, defined as those
patients initiating lamotrigine in combination with
a previously prescribed other antiepileptic drug, the
First-Line group, defined as patients untreated dur-
ing the previous 12 months initiating lamotrigine in
monotherapy, the Switch group, defined as those
patients initiating lamotrigine as monotherapy in
the place of a previously prescribed other antiepi-
leptic drug, also given as monotherapy, and the
Step-Down group, defined as those patients pre-
viously treated with lamotrigine in combination
with another antiepileptic drug, in whom the other
drug was discontinued so that the patient remained
on lamotrigine as monotherapy.
Data collection
At inclusion, data on sociodemographics, epilepsy
historyandpastandpresent treatmentwas recorded.
The participating physician completed a question-
naire on familial and personal antecedents, clinical
presentation and reasons for changing treatment.
The presence or absence of neuropsychiatric
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QOLIE-31 quality of life questionnaire. If patients
returned for a spontaneous or programmed follow-
up consultation, they filled in a second QOLIE-31
questionnaire. A 6-month cut-off was imposed and
patients returning for a secondconsultation after this
time were not included in the analysis.
Quality of life measurement
In the QOLIE-31, 30 items are organized into seven
subscales: seizure worry, overall QOL, emotional
well-being, energy—fatigue, cognitive functioning,
medication effects, and social functioning. An addi-
tional item assessing overall health status is also
included. Details of the scoring system are provided
in the QOLIE-31 Scoring Manual.13 The raw scores
were rescaled from 0 to 100 with higher values
reflecting better QOL. An overall score was obtained
by summing the scale scores after weighting using
empirically derived coefficients provided in the
Scoring Manual. The validated French version of
the QOLIE-3115,26 was used. In the case of missing
data for a single item, the entire scale was consid-
ered null and the subject was not included in the
analysis, except for the item related to driving (for
which data were missing considerably more fre-
quently, due to the high proportion of subjects with
epilepsy who do not drive), in which case the mean
score of the group for the driving item was assigned
to subjects for whom this item was missing.Statistical analysis
The study population for the present analysis was
defined as all subjects aged at least 16 years (since
the QOLIE-31 is not validated for younger children)
who had returned for a second consultation
between 3 and 6 months after the inclusion visit,
and who provided data allowing calculation of the
global QOLIE-31 score at both visits.
The size of the study samplewas chosen in order to
detect significant differences in the primary pharma-
coepidemiological outcomes of the study at inclu-
sion. Given that follow-up consultations were not
protocol-imposed due to the observational nature
of the study, and that the rate of follow-up consulta-
tion was thus unpredictable, no specific a priori
statistical power calculations relative to the quality
of life datawereperformed.However, a posteriori, it
was determined that the actual sample size achieved
would allow demonstration of a difference in total
QOLIE-31 score between the four groupswith a power
of 80%, assuming an average overall score of 50, an a-
risk of 0.05, and a proportional variance of 0.8.Baseline variables were compared using the x2-
test or Fisher’s exact test for categorical variables
and Student’s t-test or the Mann-Whitney U-test for
quantitative variables as appropriate. Changes in
QOLIE-31 scores over the study period were com-
pared in two ways. Firstly, the mean change from
baseline was calculated and compared between the
four treatment regimens by analysis of variance
(ANOVA). Secondly, the proportion of responders
in each treatment regimen was calculated with
its 95% confidence limits and compared with the
Cochran-Mantel-Haentzel test. Response was
defined as an improvement over baseline of at least
11.8 points, a threshold for clinically relevant
change identified during the original validation of
the QOLIE-31.21 Potential demographic and clinical
determinants of change in quality of life were eval-
uated by multiple logistic regression analysis. The
sample was divided into two groups, responders
(those subjects whose QOLIE-31 score improved
by at least 11.8 between the two consultations)
and non-responders. The independent variables
assessed in the model were age, gender, epilepsy
type, epilepsy duration, seizure frequency, antece-
dents of hospitalisation for tonic-clonic convulsions,
presence of associated neuropsychiatric morbidity,
investigator type and lamotrigine treatment regi-
men. In a first step, the influence of each variable on
quality of life outcome was assessed using a step-
wise model. Those variables associated with quality
of life outcome at a probability level of <0.1 were
subsequently entered into a multivariate regression
analysis.
Two-sided statistical tests were used throughout
and a probability level of 0.05 was considered sta-
tistically significant. All data were analysed cen-
trally using the 6.12 version of the SAS software.
Ethics
This study was performed within the framework of
the Declaration of Helsinki guidelines for clinical
research. Since participation in the study did not
affect patient care, formal Ethics Committee
approval was not required. The study was approved
by the Conseil National d’lnformatique et Liberte´,
which ensures that all medical information is kept
confidential and anonymous.Results
Subjects included
Two hundred neurologists participated in the main
part of the study (Add-on, Switch and Step-down
Lamotrigine therapy and quality of life 177groups), who saw in consultation 2634 subjects
treated with lamotrigine over a 6-month period,
the remainder not changing lamotrigine treatment
regimen at the reference consultation. Of these,
626 fulfilled inclusion criteria for one of the three
treatment groups. The majority of these eligible
patients (76.4%) corresponded to patients in whom
lamotrigine was initiated in combination with a
previously prescribed other antiepileptic drug. In
the ancillary study (First-line group), 118 neurol-
ogists included 250 patients in whom lamotrigine
had been initiated as a first-line monotherapy.
From the total eligible sample of 876 (626 from
the main study and 250 from the ancillary study),
818 (93%) were aged over 16 and thus were candi-
dates for the QOLIE-31 questionnaire. At the end of
the 4-month study period, 562 patients (64.2% of
the eligible sample) had returned for a second
consultation, 341 (38.9% of the eligible sample
and 60.7% of the followed-up patients) for whom
a global QOLIE-31 score could be calculated at both
study visits. These 341 analysable patients consist
of 192 subjects in the Add-on group, 45 in the
Switch group, 14 in the Step-down group and
90 in the First-line group. The disposition of
patients through the study is presented as a Venn
diagram in Fig. 1.
Themean interval between the two consultations
varied from 119.6  13.1 to 121.6  13.2 days in the
four groups. At the time of the second consultation,
>90% of subjects had been treated with lamotrigine
for between 3 and 6 months, except for the First-Figure 1 Patient disposition during the study. Screened patie
all screened patients changing lamotrigine treatment regime
group: patients initiating lamotrigine monotherapy; QOLIE-3
completed the QOLIE-31 questionnaire; followed-up patie
consultation; analysable patients: all followed-up patients f
both study visits. The final patient numbers for the four treat
the dark circles.line group, for whom this was the case for only 75.8%
of subjects.
Description of study population
The demographic and clinical features of the study
sample displayed according to treatment regimen
are presented in Table 1. There was a slight pre-
ponderance of female subjects included in the Add-
on and First-line arms. The average age of the
subjects was 37.7 years (S.D. 16.7; median 34), with
no significant differences being observed between
the groups.
The majority of subjects (50% in the First-line
arm and >85% in the other arms) had been diag-
nosed with epilepsy for over 1 year. Overall, a higher
proportion of subjects presented with generalised
(56.3%) than with focal (42.5%) seizures, although
there were significant inter-group differences with
generalised seizures being relatively more frequent
in the Switch arm. The most frequent epilepsy
syndromes encountered in all arms were idiopathic
epilepsies, followed by symptomatic epilepsies and
cryptogenic epilepsies. With the exception of the
Add-on group, of whom 49.5% were experiencing
seizures once a month or more, seizure control was
reasonable. Antecedents of hospitalisation for sta-
tus epilepticuswere comparatively infrequent, con-
cerning 7.0% of subjects overall, especially in the
First-line group in which only three subjects were
concerned. Cognitive or behavioural symptoms,
principally intellectual or mental retardation andnts: all patients prescribed lamotrigine; eligible patients:
n (Add-on, Switch or Step-down monotherapy): first-line
1 patients: all eligible patients over 16 years of age who
nts: all QOLIE-31 patients who returned for a second
or whom a global QOLIE-31 score could be calculated at
ment groups in the analysable population are indicated in
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Figure 2 Global QOLIE-31 scores at inclusion (&) and at
the second consultation (&). Data are presented as mean
values with 95% confidence intervals.
Table 1 Demographic and clinical characteristics of patients included into the study and all patients over 16 years
Add-on Switch Step-down First-line Total All 16 years
N = 192 N = 45 N = 14 N = 90 N = 341 N = 818
Gender
Male 86 (44.8%) 23 (51.1%) 7 (50.0%) 34 (37.8%) 150 (44.0%) 364 (44.5%)
Female 106 (55.2%) 22 (48.9%) 7 (50.0%) 56 (62.2%) 191 (56.0%) 454 (55.5%)
Age
Mean (S.D.) 37.5 (15.1) 38.1 (15.0) 31.2 (11.7) 38.9 (20.9) 37.7 (16.7) 38.1 (17.0)
Median (range) 35.5 (16—76) 37.0 (16—68) 31.0 (16—55) 30.5 (16—86) 34.0 (16—86) 35.0 (16—94)
Epilepsy duration
<1 month 2 (1.0%) 1 (2.2%) — 19 (22.1%) 22 (6.5%) 54 (6.7%)
1—3 months 4 (2.1%) — — 9 (10.5%) 13 (3.9%) 41 (5.1%)
4—11 months 12 (6.3%) 4 (8.9%) 1 (7.1%) 15 (17.4%) 32 (9.5%) 79 (9.8%)
1—5 years 42 (21.9%) 17 (37.8%) 3 (21.4%) 28 (32.6%) 90 (26.7%) 199 (24.7%)
>5 years 132 (68.8%) 23 (51.1%) 10 (71.4%) 15 (17.4%) 180 (53.4%) 432 (53.7%)
Type of epilepsy
Generalised 100 (52.1%) 35 (77.8%) 7 (50.0%) 50 (55.6%) 192 (56.3%) 444 (54.4%)
Focal 92 (47.9%) 10 (22.2%) 7 (50.0%) 36 (40.0%) 145 (42.5%) 362 (44.4%)
Undetermined — — — 4 (4.4%) 4 (1.2%) 10 (1.2%)
Idiopathic 78 (40.6%) 22 (48.9%) 5 (38.5%) 34 (37.8%) 139 (40.9%) 317 (39.1%)
Cryptogenic 61 (31.8%) 18 (40.0%) 4 (30.8%) 23 (25.6%) 106 (31.2%) 271 (33.4%)
Symptomatic 53 (27.6%) 5 (11.1%) 4 (30.8%) 20 (22.2%) 82 (24.1%) 197 (24.3%)
Not specified — — — 13 (14.4%) 13 (3.8%) 26 (3.2%)
Seizure frequency
<3 per year 66 (34.4%) 30 (66.7%) 5 (35.7%) 57 (63.3%) 158 (46.3%) 374 (45.9%)
4—11 per year 31 (16.1%) 6 (13.3%) 3 (21.4%) 11 (12.2%) 51 (15.0%) 124 (15.2%)
1—3 per month 45 (23.4%) 8 (17.8%) 3 (21.4%) 10 (11.1%) 66 (19.4%) 169 (20.8%)
4—30 per month 38 (19.8%) 0 (0.0%) 2 (14.3%) 11 (12.2%) 51 (15.0%) 120 (14.7%)
30 per month 12 (6.3%) 1 (2.2%) 1 (7.1%) 1 (1.1%) 15 (4.4%) 27 (3.3%)
Hospitalisation 15 (7.8%) 4 (8.9%) 2 (14.3%) 3 (3.3%) 24 (7.0%) 60 (6.4%)
NP comorbidity 40 (20.8%) 7 (15.9%) 4 (28.6%) 7 (7.9%) 58 (17.1%) 165 (20.4%)
Hospitalisation refers to antecedents of hospitalisation for tonic-clonic convulsions. NP comorbidity: neuropsychiatric comorbidity.depression, were present in 17.1% of the subjects
included.
There were no significant differences in any of the
demographic or clinical features of the study popula-
tion compared to the total group of 818 subjects aged
16 or over included in the study (Table 1), except
for neuropsychiatric comorbidity, less frequently
reported for participants (p = 0.049).
Quality of life
Two validated QOLIE-31 questionnaires were
returned by 341 subjects. At the baseline visit,
the global score on the QOLIE-31 varied from 53.8
[95% confidence intervals: 51.2—56.3] in the Add-on
group to 61.5 [95% confidence intervals: 58.4—64.7]
in the First-line group (Fig. 2). These between-
group differences were significant ( p = 0.006;
ANOVA). The mean value for the entire sample
was 56.7 [95% confidence intervals: 54.9—58.6].
The overall standardised Cronbach’s a coefficient
was 0.94.At the time of the second consultation, global
QOLIE-31 scores had increased in each group
(Fig. 2). The mean change from baseline was 8.76
[95% confidence intervals: 7.2—10.3], being lowest
in the Switch group and highest in the Add-on group
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Table 2 Mean change from baseline in QOLIE-31 global score
Group N Change (95% CI) p (ANOVA) Responders
Add-on 192 10.4 (8.4—12.4) <0.0001 70 36.5% (29.65—43.27%)
Switch 45 5.6 (1.1—10.1) 0.0181 11 24.4% (11.89—37%)
Step-down 14 6.5 (1.0—11.9) 0.0363 4 28.6% (4.91—52.24%)
First-line 90 7.5 (4.2—10.1) <0.0001 33 36.7% (26.71—46.62%)
All groups 341 8.8 (7.2—10.3) <0.0001 118 34.6% (29.56—39.65%)
Responders are defined as those subjects whose global scores improved by at least 11.8 points. Data for responders are presented as
absolute number of subjects and as a percentage with 95% confidence intervals.(Table 2). This change in score was statistically
significant (p < 0.05) in each treatment group,
but there was no significant interaction between
change from baseline and treatment group
( p = 0.10). The proportion of subjects whose global
QOLIE-31 scores improved by more than 11.8 points
between the two consultations was 34.6%, with no
significant difference between the four treatment
groups ( p = 0.45; Table 2).
Global QOLIE-31 scores were also analysed
according to treating physician. At the inclusion
visit, quality of life scores were very similar irre-
spective of the type of neurologist treating the
patient (p = 0.84). The degree of improvement
was significant ( p < 0.001) and somewhat greater
in patients treated by a community neurologist
compared with those followed by epilepsy specia-
lists, although the interaction between change from
baseline and physician group was not significant
( p = 0.79; Table 3).
Concerning the seven individual QOLIE-31 sub-
scores, the lowest scores at baseline were observed
for the energy—fatigue subscore, except for the
Step-down and First-line groups, in which the low-
est scores were obtained for seizure worry (Fig. 3).
The two dimensions for which there a significant
difference in baseline score was observed between
study groups were the social functioning dimension
( p < 0.001), lowest in the Add-on and highest in the
First-line group and the cognitive functioning
dimension (p = 0.017), lowest in the Step-down
and highest in the First-line group. Significant
improvements were observed for all the subscores
in the Add-on and First-line groups and for the
overall QOL, energy—fatigue, medication effects,Table 3 QOLIE-31 global scores at inclusion and the sec
consultations according to physician type
Physician N Inclusion
Community neurologist 136 57.0 (54.1—59.8)
Hospital neurologist 93 56.6 (52.9—60.3)
Epilepsy specialist 112 56.5 (53.3—59.7)
All physicians 341 56.7 (54.9—58.6)
Data are given as mean values with 95% confidence intervals. Proband social functioning subscales for the Switch
group. In the Step-down group, which contained
only 14 subjects, significant improvement was only
observed on the energy—fatigue subscale. No dete-
rioration of quality of life was observed on any
subscale in any group. In the Add-on group, improve-
ments in score were quite similar across subscores
and generally higher than in the other groups, with
the largest effects observed for the energy—fatigue
and medication effects subscores. In the Switch
group, improvements were quite variable, but lar-
gest for the medication effects subscore. In the
Step-down group, improvements were generally less
marked than in the other groups, except for the
energy—fatigue subscore, which improved the most
in this group. In the First-line group, changes were
also variable with the largest improvement seen for
the seizure worry subscore. Significant differences
in extent of change between the two consultations
between the treatment arms were observed on the
seizure worry dimension (p = 0.04; smallest change
in the Switch group and largest change in the First-
Line group) and on the energy—fatigue dimension
(p = 0.01; smallest change in the First-Line group
and largest change in the Add-on group).
Determinants of improvement in quality of
life
A preliminary univariate logistic regression analysis
was performed to identify potential determinants of
improvement (defined as an increase of global score
of at least 11.8 points between the two consulta-
tions). The variables evaluated are listed in Table 4.
Focal or undetermined seizure type and high seizureond consultation, and change from baseline between
Second visit Change p
66.4 (63.9—68.8) 9.4 (7.0—11.8) <0.0001
65.1 (61.9—68.4) 8.5 (5.7—11.3) <0.0001
64.7 (61.5—67.8) 8.2 (5.4—11.0) <0.0001
65.5 (63.8—67.2) 8.8 (7.2—10.3) <0.0001
ability values were determined with ANOVA.
180 H. Allain et al.
Figure 3 Evolution of quality of life during the study in the Add-on (A), Switch (B), Step-down (C) and First-line (D)
groups. Data are presented as scores on the QOLIE-31 subscales at inclusion (^) and at the follow-up consultation (&).
Each axis of the radar plot represents one of the seven dimensions of the QOLIE-31. Probability values refer to differences
in score between inclusion and at the second consultation.frequency at inclusion were the only variables asso-
ciated with a greater probability of attaining a
higher quality of life score. When these two vari-
ables, together with age and gender, were entered
into a stepwise multivariate logistic regression
model, only seizure type was retained as a signifi-
cant determinant of improvement of quality of life
( p = 0.0195; odds ratio for focal epilepsy versus
generalised epilepsy: 1.58 [0.98—2.57]; for under-
mined epilepsy versus generalised epilepsy: 2.59
[95% confidence intervals: 1.26—5.35]).Discussion
This study demonstrated that initiation of lamotri-
gine treatment is associated with improvement of
quality of life measured with the QOLIE-31 in an
unselected population of subjects with epilepsy
treated in the community. The baseline scores for
the QOLIE-31 that were measured are comparable
with those reported previously in more structured
clinical trials of lamotrigine monotherapy intro-
duced either as a switch from previous antiepileptic
medication25 or as a reduction to monotherapy from
a combination.33 The mean score at baseline was
lower than that reported in the validation study ofthe QOLIE-31 (56.7 versus 61.9).26 However, unlike
in the validation study, it should be noted that all
patients in the present study were considered to be
insufficiently controlled to consider a change in
treatment necessary. The order of scores on the
various subscales was also similar to that observed
in the validation study, with the exception of the
medication effects dimension, rated fourth in this
study compared to second in the validation study,
and the seizure worry dimension, rated seventh and
fifth, respectively. Cronbach’s a coefficient was 0.86
in the validation study compared to 0.94 in the
present study. Baseline scores were highest in the
First-line monotherapy group, which represent
essentially recently-diagnosed patients or those
whose epilepsy did not warrant previous treatment,
and lowest in the Add-on group, who may represent
the more refractory patients in whom satisfactory
seizure control was not achievable with previous
monotherapy regimens with other drugs.
After initiation of lamotrigine treatment, QOLIE-
31 scores increased in all treatment groups.
Although the extent of improvement varied
between the groups, the final QOLIE-31 scores
obtained at the end of the 4-month observation
period were similar across groups, as was the pro-
portion of responders (defined as an increase in
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Table 4 Variables evaluated in logistic regression analysis for an association with an improvement in quality of life
corresponding to an increase in QOLIE-31 score of at least 11.8 points
No improvement (N = 223) Improvement (N = 118) Total (N = 341) Odds ratio p
Age (mean  S.D.) 38.0  17.1 (223) 37.1  16.1 (118) 37.7  16.7 (341) 1.00 (0.98; 1.01) 0.773a
Gender
Female 124 (55.6%) 67 (56.8%) 191 (56.0%) 1.00 0.835b
Male 99 (44.4%) 51 (43.2%) 150 (44.0%) 0.95 (0.61; 1.50)
Seizure type
Generalised 114 (51.1%) 44 (37.3%) 158 (46.3%) 1.00 0.019b
Focal 90 (40.4%) 55 (46.6%) 145 (42.5%) 1.58 (0.98; 2.57)
Undetermined 19 (8.5%) 19 (16.1%) 38 (11.1%) 2.59 (1.25; 5.35)
Epilepsy type No improvement (N = 222) Improvement (N = 118) Total (N = 340) Odds ratio p
Idiopathic 88 (39.6%) 51 (43.2%) 139 (40.9%) 1.00
Symptomatic 71 (32.0%) 35 (29.7%) 106 (31.2%) 0.85 (0.50; 1.45) 0.932c
Cryptogenic 54 (24.3%) 28 (23.7%) 82 (24.1%) 0.89 (0.50; 1.59)
Not specified 9 (4.1%) 4 (3.4%) 13 (3.8%) 0.77 (0.22; 2.62)
Duration of epilepsy No improvement (N = 221) Improvement (N = 116) Total (N = 337) Odds ratio p
<1 month 17 (7.7%) 5 (4.3%) 22 (6.5%) 1.00
1—3 months 8 (3.6%) 5 (4.3%) 13 (3.9%) 2.12 (0.48; 9.50) 0.761a
4—11 months 19 (8.6%) 13 (11.2%) 32 (9.5%) 2.33 (0.69; 7.89)
1—5 years 60 (27.1%) 30 (25.9%) 90 (26.7%) 1.70 (0.57; 5.05)
>5 years 117 (52.9%) 63 (54.3%) 180 (53.4%) 1.83 (0.65; 5.20)
Seizure frequency No improvement (N = 223) Improvement (N = 118) Total (N = 341) Odds ratio p
3 per year 111 (49.8%) 47 (39.8%) 158 (46.3%) 1.00
4—11 per year 34 (15.2%) 17 (14.4%) 51 (15.0%) 1.18 (0.60; 2.32) 0.050 a
1—3 per month 38 (17.0%) 28 (23.7%) 66 (19.4%) 1.74 (0.96; 3.16)
4—30 per month 34 (15.2%) 17 (14.4%) 51 (15.0%) 1.18 (0.60; 2.32)
>30 per month 6 (2.7%) 9 (7.6%) 15 (4.4%) 3.54 (1.19; 10.51)
Hospitalisation for SE
None 206 (92.4%) 111 (94.1%) 317 (93.0%) 1.00 0.379c
One or two 14 (6.3%) 4 (3.4%) 18 (5.3%) 0.53 (0.17; 1.65)
Three or more 3 (1.3%) 3 (2.5%) 6 (1.8%) 1.86 (0.37; 9.35)
NP comorbidity No improvement (N = 222) Improvement (N = 117) Total (N = 339) Odds ratio p
None 187 (84.2%) 94 (80.3%) 281 (82.9%) 1.00 0.366b
Present 35 (15.8%) 23 (19.7%) 58 (17.1%) 1.31 (0.73; 2.34)
Neurologist
Epilepsy specialist 68 (30.5%) 44 (37.3%) 112 (32.8%) 1.00 0.377b
Hospital 65 (29.1%) 28 (23.7%) 93 (27.3%) 0.67 (0.37; 1.19)
Community 90 (40.4%) 46 (39.0%) 136 (39.9%) 0.79 (0.47; 1.33)
Treatment regimen
First-line 57 (25.6%) 33 (28.0%) 90 (26.4%) 1.00
Add-on 122 (54.7%) 70 (59.3%) 192 (56.3%) 0.99 (0.59; 1.67) 0.447c
Switch 34 (15.2%) 11 (9.3%) 45 (13.2%) 0.56 (0.25; 1.25)
Step-down 10 (4.5%) 4 (3.4%) 14 (4.1%) 0.69 (0.20; 2.38)
Where data were missing, the sample size for the analysis (N) is indicated. Significant associations ( p < 0.10) between proportion of
improvers and baseline variables, retained in the multivariate analysis, are indicated in bold.
a Kruskall-Wallis test.
b Pearson x2-test.
c Fisher’s exact test.score of more than 11.8). The largest improvement
was observed for the Add-on group. The logistic
analysis did not, however, identify treatment regi-men as being a significant determinant of quality of
life improvement, although the power of this ana-
lysis may have been restricted by the relatively
182 H. Allain et al.small number of subjects in the Switch and Step-
down groups. The improvement in quality of life
observed was somewhat lower than reported in the
clinical trials (mean change: 9.6 for a switch regi-
men and 14.6 for a reduction regimen).25,33 This
difference could probably be explained by the lack
of a protocol-defined follow-up visit in this observa-
tional study, with the consequence that patients
who are doing well following the treatment change,
and who are thus less likely to return for a consulta-
tion, may be under-represented in our study sample
compared to randomised clinical trials in which
follow-up is structured.
During the validation of the QOLIE-31, an attempt
was made to define the minimum important clinical
change in score using patients’ subjective report of
amelioration.21 Although the mean changes
observed in our study are beneath this threshold
(+11.8), around one-third of treated patients
achieved this level of response. Nonetheless, it
should be noted that the extent such thresholds
can be generalised cross-culturally and outside
the setting of a structured clinical trial is not clear.
For example, important cross-cultural differences
in the perceived impact of epilepsy have been
demonstrated between several European countries
using the SF-36.38 During our study, data on patient
satisfaction was not obtained whereby the minimum
important clinical change could have been cali-
brated independently for our naturalistic treatment
setting.
There were no differences in baseline QOLIE-31
scores between treatment setting, although there
was a trend towards greater improvement in quality
of life in subjects treated by a community neurol-
ogist compared to by an epilepsy specialist. In a
recent survey in the Netherlands,39 QOLIE-31 scores
were found to be significantly higher in patients with
epilepsy managed in primary care compared to
those managed in a hospital neurology department
or in a specialist epilepsy centre, a difference
attributed to the greater disease severity in patients
treated in the latter setting. Although we found that
patients treated by epilepsy specialists were likely
to present more severe epilepsy than those treated
by a community-based neurologist, this difference
may not be sufficiently important to translate into
significantly worse quality of life.
The subscales that improved the most with lamo-
trigine treatment were energy—fatigue and medi-
cation effects. This is consistent with what is known
of the side-effect profile of lamotrigine, which pro-
duces little sedative effects or cognitive impairment
compared to many other antiepileptic drugs, nota-
bly those with a GABAergic mechanism of action.
These two subscales were also identified as beingthe most sensitive in the clinical trials.25,33 An
exception to this finding was observed in the
First-line group, in which the most sensitive sub-
scale was seizure worry. Baseline values on this
subscale were particularly low in this group, as
might be expected in patients who had only recently
entered epilepsy management.
Importantly, no deterioration in the cognitive
functioning dimension of the QOLIE-31 was observed
following initiation of lamotrigine treatment and
scores indeed improved in the First-line and Add-
on groups. This is consistent with the notion that
lamotrigine has little influence on cognitive, intel-
lectual and behavioural function compared to other
antiepileptic drugs.36
Using logistic regression analysis, demographic
and clinical variables were screened for an associa-
tion with improvement of quality of life. Seizure
type was the only such variable to be identified.
Cramer et al.33 reported that improvement in sei-
zure control was associated with larger changes in
QOLIE-31 scores in their sample of 151 patients
treated with lamotrigine, but were unable to iden-
tify any baseline variables that were determinants
of improvement, apart from baseline QOLIE-31
score. Data on clinical outcome was not collected
in this study so improvements of seizure control
could not be assessed in our model. Seizure fre-
quency, which was identified in the univariate but
not the multivariate analysis, has previously been
demonstrated to be a determinant of poor quality of
life as measured with the QOLIE-31.26
In the Switch group, improvements were
observed for energy—fatigue, medication effects,
overall quality of life and social functioning sub-
scales. Randomised comparative studies have shown
a superior improvement in quality of life with
respect to medication side-effects following initia-
tion of lamotrigine treatment compared to pheny-
toin34 and carbamazepine35 using the SEALS
inventory and compared to valproate using the
QOLIE-89.31 Carbamazepine and valproate were
the most widely used previous treatments in the
Switch group in our study.37
A series of studies in Spain have evaluated
improvements in quality of life in patients initiating
therapy with a series of second-generation AEDs
using the QOLIE-31 or QOLIE-10. These assessed
oxcarbazepine monotherapy as first-line or substi-
tution treatment (QOLIE-31),24 levetiracetam as
adjunctive treatment (QOLIE-10)40 and gabapentin
monotherapy as first-line or substitution treatment
(QOLIE-10).41,42 All these treatments improved the
global QOLIE score and, in the case of gabapentin,
the improvement was observed for all items of the
QOLIE-10. Data for individual items or subscales was
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tam studies.
Add-on treatment with levetiracetam was also
evaluated in a randomised placebo-controlled trial
using the QOLIE-31.23,43 This showed sustained ame-
lioration in global score in the levetiracetam treat-
ment group, but the only subscores for which a
significant improvement was observed were seizure
worry and overall quality of life. Adjunctive therapy
with gabapentin has also been shown to improve
QOLIE-10 scores in an open-label studies performed
in Australia and Canada.44,45 On the other hand, no
improvement in quality of life was shown following
initiation of adjunctive therapy with either topir-
amate using a generic quality of life measure, the
SF3646 or vigabatrin.47,48
The study has several limitations. Given the
observational nature of the study, it was not possible
to impose dedicated follow-up visits on patients
during the study period. For this reason, a significant
proportion of subjects (39%) did not return for a
programmed or spontaneous follow-up consultation
during the study period. This reduces the power of
the study to detect significant inter-group differ-
ences, notably for the Switch and Step-down treat-
ment groups, where patient numbers are low. In
addition, incomplete follow-up may also introduce
bias, if patients who are doing better on treatment
are less likely to return for a consultation, thus
leading to an under-estimate of the effect size on
quality of life. The fact that data were not collected
simultaneously and by the same panel of neurolo-
gists for the First-line group and the other three
groups is also problematical, and may be a source of
bias. This constraint was however unavoidable due
to the comparatively recent approval of lamotrigine
for first-line monotherapy of epilepsy in France. The
observation period of 6 months is also relatively
short and patients may not have reached a stable
plateau of quality of life. Nonetheless, quality of life
benefits with lamotrigine have been reported else-
where to be stable over time for up to 5 years.49
Finally, the study did not collect data on clinical
outcome after initiation of lamotrigine therapy.
Many clinical variables, such as seizure frequency
and side-effects of antiepileptic drugs are known to
influence quality of life as measured with the QOLIE-
3126 and inclusion of these into the logistic analysis
of determinants of improvement in quality of life
could have provided a pertinent refinement of the
model and shed light on inter-group comparisons.
Information on subjective perception of ameliora-
tion could have helped calibrate the changes in
QOLIE-31 scores observed.
In conclusion, this observational study has
demonstrated that epilepsy therapy with lamotri-gine in a naturalistic treatment setting is associated
with a significant improvement of quality of life,
regardless of the treatment regimen used.References
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